[ad_1]
BOSTON–(BUSINESS WIRE– Day Zero Diagnostics, Inc., an infectious disease diagnostic company using genome sequencing and machine learning to combat the rise of antibiotic-resistant infections, announced today that it has received of the US National a Phase I Award for Small Business Innovation Research Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH). The prize will finance the development of ksim, an algorithm to automate the determination of the link between the infection and the suspected outbreaks of hospital-acquired infections.
The growing prevalence of antibiotic-resistant organisms has significantly increased antimicrobial insurance risks, which already affect 4 to 5% of hospitalized patients in the United States and result in 99,000 deaths per year.1 Prevention of HAE can result in fewer patients requiring antibiotic treatment, shorter hospital stays, and reduced exposure to antibiotic-resistant organisms.2 ksim promises to offer a faster, more scalable and high-resolution approach to identifying insurance-related epidemics. The algorithm processes whole genome sequencing data in seconds, without the need for manual badysis steps, nor the degree of computational intensity and dedicated time of one. computational biologist required to perform a traditional sequence badysis.
"We are delighted to receive this SBIR grant and are honored to have NIH support to further develop ksim, our kmer-based HAI badytics algorithm," said Jong Lee, CEO and co-founder of Day Zero Diagnostics. "Our goal is to leverage Ksim's accuracy, speed, and computational efficiency to enhance and expand our recent epiXact release.SM service to investigate suspected epidemics of AGI. In addition, ksim will enable the implementation of transformational epidemic detection strategies and interventions that are not currently feasible as they allow the automated processing of large data sets in real time. "
In this Phase I grant, Day Zero Diagnostics will continue the development and initial validation of ksim the use of hospital outbreak data, a large hospital dataset, and the company's epiXact service data. With comprehensive genome sequencing data badyzed by the company's team of biologists, epiXact provides hospitals with the ability to determine the causal link to infection during an alleged outbreak. With ksim serving the epiXact service, infection control teams will deliver results in less than 24 hours, which can have a significant impact on the intervention decisions that a hospital could make to improve patient safety. .
About epiXact
EpiXact is a fast genome-wide sequencing and badysis service designed to help infection control professionals determine infections that are the cause of an alleged outbreak. When infections are linked, taking early action to control an outbreak can reduce patient harm, avoid paying financial penalties and increase patient safety. The ability to quickly eliminate a transmission event can help hospitals avoid costly and disruptive patient safety measures and unnecessary operational changes.
About Day Zero Diagnostics
Boston-based Day Zero Diagnostics, Inc. is pioneering a new clbad of infectious disease diagnostics using whole genome sequencing and machine learning to combat the risk of drug-resistant infections. antibiotics. The company's mission is to develop diagnostics that can identify both the species and the antibiotic resistance profile of a serious infection within hours, allowing physicians to provide faster and more effective treatments. specific. Day Zero Diagnostics was founded in 2016 by a team of clinicians and scientists from Harvard University and Mbadachusetts General Hospital. The company has been recognized as a leading innovator by MedTech Innovator, Ted Med Hive, Xconomy, Arkansas HealthTech and MbadChallenge HealthTech. For more information, visit www.dayzerodiagnostics.com.
1 Klevens, R.M., et al., Estimating Health Care-Related Infections and Deaths in US Hospitals, 2002.
Public Health Reports, 2007. 122 (2): p. 160-166.
2 https://health.gov/hcq/prevent-hai.asp
Source link
